<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578344</url>
  </required_header>
  <id_info>
    <org_study_id>H-16447-SCALLOP</org_study_id>
    <secondary_id>SCALLOP</secondary_id>
    <nct_id>NCT00578344</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP</brief_title>
  <acronym>SCALLOP</acronym>
  <official_title>Allogeneic Bone Marrow Transplantation From HLA Identical Related Donors for Patients With Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, or Hemoglobin SB0/+ Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tami D. John</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients are being asked to participate in this study because they have severe sickle cell&#xD;
      anemia (SCD) with or without the beta thalassemia trait. Sickle cell anemia is an illness&#xD;
      where the red blood cells change shape and can clog up blood vessels. This keeps the body&#xD;
      from getting the oxygen it needs. Thalassemia is when the body does not make enough&#xD;
      hemoglobin, something that helps the oxygen get to the places it needs to go in the body. The&#xD;
      patient may or may not need to get regular blood transfusions (getting more blood) to improve&#xD;
      their quality of life (feel better) and prevent organ damage (problems with the brain, heart,&#xD;
      lung, kidney, and gonad, for example.). The transfusions can also cause problems, including&#xD;
      iron overload (too much iron in the blood), which can be fatal (patients can die) without&#xD;
      regular deferoxamine shots. Even with the best usual treatments, people with thalassemia or&#xD;
      SCD die sooner. There is no proven cure.&#xD;
&#xD;
      We would like to treat patients using bone marrow transplantation, a treatment that has been&#xD;
      used for people with SCD. The transplant uses healthy &quot;matched&quot; bone marrow. This comes from&#xD;
      a brother or sister who does not have sickle cell disease or severe thalassemia. If the&#xD;
      treatment works, the sickle cell disease or thalassemia may be cured. This treatment has been&#xD;
      used to treat patients with sickle cell disease or thalassemia. It has worked in most cases.&#xD;
      We hope, but cannot promise, that the transplanted marrow will make healthy cells, and&#xD;
      patients will not have sickle cell disease or severe thalassemia anymore.&#xD;
&#xD;
      We do not know what effect this treatment will have on the damage that has already been done&#xD;
      by the disease. Finding that out is the main reason for this study. Currently, very little&#xD;
      has been reported about organ function after bone marrow transplants in patients with sickle&#xD;
      cell anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to any bone marrow transplant, we will need patients to:&#xD;
&#xD;
        -  Answer questions about their medical history;&#xD;
&#xD;
        -  Undergo a physical examination;&#xD;
&#xD;
        -  Have tests done to see how well the lungs are working;&#xD;
&#xD;
        -  Have a chest x-ray;&#xD;
&#xD;
        -  Have an EKG to look at the heart;&#xD;
&#xD;
        -  Have an MRI &amp; MRA (Magnetic Resonance Angiography, which looks at the blood vessels and&#xD;
           the blood flowing through them). These 2 tests will look to see if the patient has had&#xD;
           any strokes;&#xD;
&#xD;
        -  Have a PET scan to look at the head and body;&#xD;
&#xD;
        -  Have a liver biopsy to determine if the liver has been damaged (which can happen from&#xD;
           iron overload that happens after many transfusions). Too much liver damage would mean a&#xD;
           transplant cannot be done.&#xD;
&#xD;
      For the liver biopsy, the skin is numbed with medicine, and a special needle goes into the&#xD;
      liver. The needle removes a very small piece of the liver (tissue). The tissue is taken and&#xD;
      examined.&#xD;
&#xD;
      Also, about 30 cc (2 tablespoons) of blood will be drawn to test the blood for viruses,&#xD;
      including HIV (the virus that causes AIDS). If the HIV test is positive, a transplant will&#xD;
      not be done because it would be too dangerous for the patient.&#xD;
&#xD;
      At least 2 weeks before the bone marrow infusion, the patient will be immunized with Prevnar&#xD;
      7. Prevnar 7 is a vaccine that is used in children to protect against some types of bacteria&#xD;
      called Streptococcus pneumoniae, which can cause the lung infection called pneumonia. People&#xD;
      with Sickle Cell anemia are at a higher risk of dying from an infection from this type of&#xD;
      bacteria. Although children are regularly given the Prevnar 7 vaccine, it is not common to&#xD;
      test a child's immune response to the vaccine. In this study, we will check the immune&#xD;
      system's response to the vaccine by drawing an extra 3 mL (less than 1 teaspoon) of blood 3&#xD;
      weeks after the patient gets the Prevnar 7 vaccine.&#xD;
&#xD;
      Just before the bone marrow transplant, we must kill the cells in the bone marrow that make&#xD;
      the abnormal red blood cells found in patients with severe thalassemia or sickle cell&#xD;
      disease. We will do this by using 3 drugs: busulfan, cyclophosphamide, and campath-1H.&#xD;
      Campath-1H is used to prevent the body from rejecting or refusing to let the donor blood&#xD;
      cells grow in the body. MESNA is given with the cyclophosphamide to prevent kidney damage.&#xD;
      Methotrexate and cyclosporin are also given to prevent graft-versus-host disease (GVHD);&#xD;
      methylprednisolone will be given after the bone marrow infusion if the patient develops GVHD.&#xD;
      A drug will also be given to prevent seizures (either dilantin or lorazepam).&#xD;
&#xD;
      Graft-versus-host disease (GVHD) is a possible side-effect of the transplant. In GVHD, some&#xD;
      cells in the donor marrow attack cells in the patient's body. This causes skin, liver, and&#xD;
      bowel problems, and may damage other parts of the body. Often, these problems are fairly&#xD;
      mild, but they can be severe or even cause death. Severe GVHD is likely to occur in about 10%&#xD;
      of patients.&#xD;
&#xD;
      After the patient gets the drug treatment, they will be given bone marrow from a brother or&#xD;
      sister who has healthy bone marrow that matches the patients. The healthy bone marrow will be&#xD;
      put into a vein (given IV) in the same way that blood transfusions are given. The marrow&#xD;
      cells then travel to the right places in the body, where they should grow and make new normal&#xD;
      blood cells.&#xD;
&#xD;
      This is the treatment schedule:&#xD;
&#xD;
      Protocol Day &amp; Treatment:&#xD;
&#xD;
      14 or more days before the bone marrow infusion -- Prevnar 7 vaccine&#xD;
&#xD;
      10 days before the bone marrow infusion -- Begin Dilantin or Lorazepam (to prevent seizures)&#xD;
&#xD;
      9 days before the bone marrow infusion -- Busulfan&#xD;
&#xD;
      8 days before the bone marrow infusion -- Busulfan&#xD;
&#xD;
      7 days before the bone marrow infusion -- Busulfan&#xD;
&#xD;
      6 days before the bone marrow infusion -- Busulfan&#xD;
&#xD;
      5 days before the bone marrow infusion -- Campath 1H, Cyclophosphamide, and MESNA&#xD;
&#xD;
      4 days before the bone marrow infusion -- Campath 1H, Cyclophosphamide, and MESNA&#xD;
&#xD;
      3 days before the bone marrow infusion -- Campath 1H, Cyclophosphamide, and MESNA&#xD;
&#xD;
      2 days before the bone marrow infusion -- Campath 1H, Cyclophosphamide, MESNA, and&#xD;
      cyclosporin&#xD;
&#xD;
      1 day before the bone marrow infusion -- DAY OF REST&#xD;
&#xD;
      Day &quot;0&quot; -- bone marrow infusion given&#xD;
&#xD;
      1 day after the bone marrow infusion -- Methotrexate&#xD;
&#xD;
      3 days after the bone marrow infusion -- Methotrexate&#xD;
&#xD;
      6 days after the bone marrow infusion -- Methotrexate&#xD;
&#xD;
      11 days after the bone marrow infusion -- Methotrexate&#xD;
&#xD;
      After transplant, Filgrastrim, a growth hormone for the bone marrow, may be given&#xD;
      intravenously (through a vein), if medically necessary.&#xD;
&#xD;
      Sometimes, the donor's bone marrow does not grow. Then, the patient would be without working&#xD;
      bone marrow cells. So that we will be ready to treat this problem if it happens, we will take&#xD;
      bone marrow from the hip bone before the patient gets the drug treatment. The patient will be&#xD;
      asleep (sedated) when the marrow is taken, and they will be given medicine for any pain they&#xD;
      have afterwards. This bone marrow will be frozen and stored or preserved. If the donor bone&#xD;
      marrow does not grow, we will thaw the stored marrow and put it back into the body. This&#xD;
      stored bone marrow should grow and produce working blood cells. If the stored bone marrow&#xD;
      must be given back, the disease will not be cured.&#xD;
&#xD;
      To tell whether the transplant has worked or &quot;engrafted&quot;, we will take samples of bone marrow&#xD;
      (bone marrow aspirate). We will do this 3 weeks after the transplant to make sure the new&#xD;
      cells are beginning to grow. We will take another marrow sample at 3 months after the&#xD;
      transplant. We want to make sure the new cells are still growing. This test will take about&#xD;
      30 to 45 minutes. Because this test is painful, the patient will be given pain medicine&#xD;
      before, during, and after the test.&#xD;
&#xD;
      The patient will need to be in the hospital for at least 3 weeks after the transplant to make&#xD;
      sure the transplant has engrafted. We will do several tests (of the lung, kidney, and liver)&#xD;
      before and after the bone marrow transplant. We want to find out how much the treatment has&#xD;
      helped the patient and how much it might help other patients. Most tests will be done every&#xD;
      week for 4 months and at each visit to the hospital. Also, we will be looking at the immune&#xD;
      function. To do this, we will take about 8 ml (less than 2 teaspoonful) at 6 months, 1 year,&#xD;
      and 2 years after the transplant. When possible, we will take the blood from an IV line that&#xD;
      the patient already has. However, at times we will have to draw the blood with another needle&#xD;
      stick. A total amount of 200 mL (about 13 tablespoons) of blood will be collected from the&#xD;
      patient during the entire study.&#xD;
&#xD;
      After 4 months, if the patient's health is good, they will not need to come to the hospital&#xD;
      so often. The visits to the doctor should be more like they were before the bone marrow&#xD;
      transplant. Since problems may happen months after the transplant and this is a new way to&#xD;
      treat sickle cell disease and thalassemia the patient will need to have exams and blood tests&#xD;
      done every few months during the first and second years after their transplant. After that,&#xD;
      if all is well, the patient will need to be examined and have blood tests 4 times a year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to no new subject enrollment during the last 3 year period.&#xD;
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Evaluated for Evidence of Recovery of Organ Function Measured Via MRI or PET Scan.</measure>
    <time_frame>One year</time_frame>
    <description>Assess Number of participants that recovered organ function diagnosed with sickle cell disease (SCD) or sickle hemoglobin variants after undergoing allogeneic SCT/BMT from HLA genotype identical donors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Pre and Post Transplant PET Scan to Assess Organ Recovery Based on Rate of Acquisition.</measure>
    <time_frame>One year</time_frame>
    <description>Number of participants that did or did not have pre- and post- PET scans.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Immune Response to Immunization After BMT in Participants With SCD, Hemoglobin SC, or Hemoglobin Sb0/+.</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Vaccine response will be measured via a humoral immunity panel evaluating streptococcus pneumonia IgG antibodies (microgram/mL). Panels are obtained pre and 1+ month post vaccination. Standard recommendations define a normal responder as having &gt;4 fold increase in antibody level in 50-70% of the serotypes found in the vaccine.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Hemoglobin SC</condition>
  <arm_group>
    <arm_group_label>Allogeneic BMT/SCT Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Busulfan, Campath 1H, Cyclophosphamide and MESNA:&#xD;
Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.&#xD;
Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.</description>
    <arm_group_label>Allogeneic BMT/SCT Transplant</arm_group_label>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Campath 1H</intervention_name>
    <description>Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.</description>
    <arm_group_label>Allogeneic BMT/SCT Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide and MESNA</intervention_name>
    <description>Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.</description>
    <arm_group_label>Allogeneic BMT/SCT Transplant</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a related HLA genotype identical donor and hemoglobin SS, hemoglobin SC,&#xD;
             or hemoglobin Sb0/+ and at least one of the following conditions:&#xD;
&#xD;
               1. Previous central nervous system vaso-occlusive episode with or without residual&#xD;
                  neurologic findings, or has an abnormal transcranial doppler exam without&#xD;
                  neurologic findings, or abnormal MRI/MRA of the brain with or without neurologic&#xD;
                  findings;&#xD;
&#xD;
               2. Frequent painful vaso-occlusive episodes which significantly interfere with&#xD;
                  normal life activities and which necessitate chronic transfusion therapy;&#xD;
&#xD;
               3. Recurrent SCD chest syndrome events, which necessitate chronic transfusion&#xD;
                  therapy;&#xD;
&#xD;
               4. Severe anemia which prevents acceptable quality of life and necessitates chronic&#xD;
                  transfusion therapy;&#xD;
&#xD;
               5. Any of the above symptoms in which the patient is not undergoing chronic&#xD;
                  transfusion therapy;&#xD;
&#xD;
               6. The patient is undergoing chronic transfusion therapy for symptoms other than&#xD;
                  those listed and which significantly interferes with normal life activities;&#xD;
&#xD;
               7. Failed hydroxyurea therapy;&#xD;
&#xD;
               8. Indication of pulmonary hypertension on 2 separate echocardiogram examinations;&#xD;
&#xD;
               9. Patients who plan to return to resource poor areas/countries.&#xD;
&#xD;
          2. Between the ages of birth and 40 years.&#xD;
&#xD;
          3. Women of childbearing potential must have a negative pregnancy test.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Patient with biopsy proven chronic active hepatitis or fibrosis with portal bridging.&#xD;
&#xD;
          2. Patient with SCD chronic lung disease &gt; stage 3 (see Appendix 1).&#xD;
&#xD;
          3. Patient with severe renal dysfunction defined as creatinine clearance &lt; 40 mL/min/1.73&#xD;
             M^2.&#xD;
&#xD;
          4. Patient with severe cardiac dysfunction defined as echocardiogram shortening fraction&#xD;
             &lt; 25% or NYHA class III or IV.&#xD;
&#xD;
          5. Patient with HIV infection.&#xD;
&#xD;
          6. Patient with unspecified chronic toxicity serious enough to detrimentally affect the&#xD;
             patient's capacity to tolerate bone marrow transplantation.&#xD;
&#xD;
          7. Patient or patient's guardian(s) unable to understand the nature and risks inherent in&#xD;
             the BMT process.&#xD;
&#xD;
          8. Pregnant/lactating women and those unwilling to use acceptable contraception will be&#xD;
             excluded.&#xD;
&#xD;
          9. Patient or patient's guardian who have not signed an informed consent.&#xD;
&#xD;
        NOTE: Patients who would be excluded from the protocol strictly for laboratory&#xD;
        abnormalities can be included at the investigator's discretion after approval by the CAGT&#xD;
        Protocol Review Committee and the FDA reviewer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tami John, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baylor College of Medicine - Texas Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <results_first_submitted>April 3, 2020</results_first_submitted>
  <results_first_submitted_qc>July 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2020</results_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Tami D. John</investigator_full_name>
    <investigator_title>Assistant Professor, Pediatrics-Hema &amp; Oncology</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>SCD</keyword>
  <keyword>Hemoglobin SS</keyword>
  <keyword>Hemoglobin SC</keyword>
  <keyword>Hemoglobin Sb0/+</keyword>
  <keyword>HLA genotype</keyword>
  <keyword>Severe anemia</keyword>
  <keyword>Transfusion therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Hemoglobin SC Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 4, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT00578344/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allogeneic BMT/SCT Transplant</title>
          <description>Busulfan, Campath 1H, Cyclophosphamide and MESNA:&#xD;
Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.&#xD;
Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest.&#xD;
Busulfan: Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.&#xD;
Campath 1H: Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.&#xD;
Cyclophosphamide and MESNA: Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insurance problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Graft failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants underwent allogeneic bone marrow transplantation from human leukocyte antigen (HLA) identical related donors with hemoglobinopathies.</population>
      <group_list>
        <group group_id="B1">
          <title>Allogeneic BMT/SCT Transplant</title>
          <description>Busulfan, Campath 1H, Cyclophosphamide and MESNA:&#xD;
Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.&#xD;
Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest.&#xD;
Busulfan: Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.&#xD;
Campath 1H: Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.&#xD;
Cyclophosphamide and MESNA: Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" lower_limit="4" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Evaluated for Evidence of Recovery of Organ Function Measured Via MRI or PET Scan.</title>
        <description>Assess Number of participants that recovered organ function diagnosed with sickle cell disease (SCD) or sickle hemoglobin variants after undergoing allogeneic SCT/BMT from HLA genotype identical donors.</description>
        <time_frame>One year</time_frame>
        <population>Out of eight participants who underwent bone marrow transplant, six participants with positron emission tomography (PET) or magnetic resonance imaging (MRI) at the time of assessment were included in the analysis. The other two were inevaluable due to graft failure or no PET or MRI at the time of assessment. Data were collected at 1 year only.</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic BMT/SCT Transplant</title>
            <description>Busulfan, Campath 1H, Cyclophosphamide and MESNA:&#xD;
Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.&#xD;
Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest.&#xD;
Busulfan: Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.&#xD;
Campath 1H: Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.&#xD;
Cyclophosphamide and MESNA: Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Evaluated for Evidence of Recovery of Organ Function Measured Via MRI or PET Scan.</title>
          <description>Assess Number of participants that recovered organ function diagnosed with sickle cell disease (SCD) or sickle hemoglobin variants after undergoing allogeneic SCT/BMT from HLA genotype identical donors.</description>
          <population>Out of eight participants who underwent bone marrow transplant, six participants with positron emission tomography (PET) or magnetic resonance imaging (MRI) at the time of assessment were included in the analysis. The other two were inevaluable due to graft failure or no PET or MRI at the time of assessment. Data were collected at 1 year only.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pre and Post Transplant PET Scan to Assess Organ Recovery Based on Rate of Acquisition.</title>
        <description>Number of participants that did or did not have pre- and post- PET scans.</description>
        <time_frame>One year</time_frame>
        <population>All participants who underwent allogeneic bone marrow transplantation from human leukocyte antigen (HLA) identical related donors with hemoglobinopathies were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic BMT/SCT Transplant</title>
            <description>Busulfan, Campath 1H, Cyclophosphamide and MESNA:&#xD;
Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.&#xD;
Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest.&#xD;
Busulfan: Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.&#xD;
Campath 1H: Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.&#xD;
Cyclophosphamide and MESNA: Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pre and Post Transplant PET Scan to Assess Organ Recovery Based on Rate of Acquisition.</title>
          <description>Number of participants that did or did not have pre- and post- PET scans.</description>
          <population>All participants who underwent allogeneic bone marrow transplantation from human leukocyte antigen (HLA) identical related donors with hemoglobinopathies were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No pre and post PET scan</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pre and post PET scan</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Immune Response to Immunization After BMT in Participants With SCD, Hemoglobin SC, or Hemoglobin Sb0/+.</title>
        <description>Vaccine response will be measured via a humoral immunity panel evaluating streptococcus pneumonia IgG antibodies (microgram/mL). Panels are obtained pre and 1+ month post vaccination. Standard recommendations define a normal responder as having &gt;4 fold increase in antibody level in 50-70% of the serotypes found in the vaccine.</description>
        <time_frame>up to 12 months</time_frame>
        <population>Out of eight participants who underwent bone marrow transplant, seven participants engrafted were included in the analysis. The other participant was excluded because he/she did not engraft and received a second transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic BMT/SCT Transplant</title>
            <description>Busulfan, Campath 1H, Cyclophosphamide and MESNA:&#xD;
Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.&#xD;
Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest.&#xD;
Busulfan: Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.&#xD;
Campath 1H: Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.&#xD;
Cyclophosphamide and MESNA: Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immune Response to Immunization After BMT in Participants With SCD, Hemoglobin SC, or Hemoglobin Sb0/+.</title>
          <description>Vaccine response will be measured via a humoral immunity panel evaluating streptococcus pneumonia IgG antibodies (microgram/mL). Panels are obtained pre and 1+ month post vaccination. Standard recommendations define a normal responder as having &gt;4 fold increase in antibody level in 50-70% of the serotypes found in the vaccine.</description>
          <population>Out of eight participants who underwent bone marrow transplant, seven participants engrafted were included in the analysis. The other participant was excluded because he/she did not engraft and received a second transplant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Primary BMT studies have a critical toxicity period of 30 days after BMT day 0. During the critical toxicity period the most severe grade of all AE's is captured. Grade 1 and 2 AEs, hematological toxicities, and fevers are excluded. Serious Adverse Events/Unanticipated Problems are reported (excluding hematological toxicities and fevers) until 100 days after BMT day 0.</time_frame>
      <desc>All adverse events were collected using CTCAE 2.0 for the study. For reporting purpose, adverse event terms were converted using CTCAE v4.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Allogeneic BMT/SCT Transplant</title>
          <description>Busulfan, Campath 1H, Cyclophosphamide and MESNA:&#xD;
Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.&#xD;
Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest.&#xD;
Busulfan: Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.&#xD;
Campath 1H: Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.&#xD;
Cyclophosphamide and MESNA: Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other: Prolonged QTc interval (QTc &gt; 0.48 seconds)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cardiac disorders - Other: Supraventricular arrhythmias (SVT/atrial fibrillation/flutter)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other: BK viremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other: Candida Albicans in tongue culture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other: Parainfluenza 3 respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tami D. John</name_or_title>
      <organization>Baylor College of Medicine/Texas Children's Hospital</organization>
      <phone>832-824-4723</phone>
      <email>tdjohn@texaschildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

